Pennington pointed out in his motion that the DEA approved as witnesses officials from Nebraska, which opposes ...

DEA and anti-cannabis group must respond to allegations of unlawful talks by November 25. Legal tensions rise ahead of ...

A researcher has filed a lawsuit against the Drug Enforcement Administration, accusing the agency of multiple legal ...

The DEA could allow more participants to testify at upcoming hearings concerning marijuana rescheduling in addition to the ...

Now a lawsuit says DEA acting in bad faith over marijuana. David Heldreth, CEO of psychedelic research firm Panacea Plant ...

The group sees Schedule III as "inadequate" for veterans' needs. But the DEA excluded it from the witness list, and a judge ...

The motion, which asks the DOJ to take over moving cannabis down the list, argues the DEA has "stacked the deck" against ...

Pam Bondi, the new nominee to the U.S. Justice Department, was an opponent of marijuana reform while serving as Florida's ...

The filing asserts that the DEA is compromised and has failed to maintain a complete record and ensure fairness and ...

The cannabis industry is concerned about the direction of regulations – and the DEA is still against the plant.

Schedule III drugs, as defined by the DEA, are "drugs with a moderate to low potential for physical and psychological ...

The rulemaking process that could lead to reclassifying marijuana is lengthy and includes a hearing in DEA administrative court. It is expected to happen in January or February, according to an ...